Skip to main content
Erschienen in: Familial Cancer 2/2013

01.06.2013 | Original Article

How do we approach the goal of identifying everybody with Lynch Syndrome?

verfasst von: Heather Hampel, Albert de la Chapelle

Erschienen in: Familial Cancer | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Excerpt

Lynch syndrome (LS) is the most common inherited cause of colorectal (CRC) and endometrial cancer. We here define LS as an individual with a germline deleterious mutation in one of the four mismatch repair (MMR) genes MSH2, MLH1, MSH6 and PMS2 or EPCAM [1]. Presently, most people diagnosed with LS have already had colorectal (CRC) endometrial (EC) or other LS-associated cancers; however, among all existing carriers of LS the majority has not (yet) had cancer. LS is currently seriously under-diagnosed. A recent study [2] of stages III and IV CRC patients in the Kaiser Permanente healthcare system found that family history documentation varied from site to site with 3 sites documenting family history on <70 % of cases and 4 sites documenting family history in over 85 % of cases. Despite the fact that in those with a documented family history, 61 % had a relative with cancer and 20 % of these had CRC in at least one first degree relative, <5 % of the population received any Lynch syndrome testing [2]. There are essentially three different approaches that can be taken to identify individuals with Lynch syndrome: (1) The current approach which is to educate providers about Lynch syndrome and then expect that they take a family history from their patients and refer appropriate patients for a cancer genetics evaluation; (2) screen all newly diagnosed CRC and EC patients for Lynch syndrome at the time of diagnosis; or (3) screen the general public for Lynch syndrome either at birth or in early adulthood. Since it is clear that the current approach is not sufficient alone, we discuss the latter two approaches here. …
Literatur
1.
Zurück zum Zitat Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J et al (2005) Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293(16):1979–1985PubMedCrossRef Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J et al (2005) Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293(16):1979–1985PubMedCrossRef
2.
Zurück zum Zitat Cross D, Rahm A, Le A, Webster J, Potosky A, Feigelson H et al (2012) PS1-08: lynch syndrome screening pattering in colorectal cancer patients in a large multi-institutional cohort. Clin Medi Res 10(3):146CrossRef Cross D, Rahm A, Le A, Webster J, Potosky A, Feigelson H et al (2012) PS1-08: lynch syndrome screening pattering in colorectal cancer patients in a large multi-institutional cohort. Clin Medi Res 10(3):146CrossRef
4.
Zurück zum Zitat Dinh TA, Rosner BI, Atwood JC, Boland CR, Syngal S, Vasen HF et al (2011) Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) 4(1):9–22CrossRef Dinh TA, Rosner BI, Atwood JC, Boland CR, Syngal S, Vasen HF et al (2011) Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) 4(1):9–22CrossRef
6.
Zurück zum Zitat Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M et al (2011) Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305(22):2304–2310PubMedCrossRef Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M et al (2011) Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305(22):2304–2310PubMedCrossRef
7.
Zurück zum Zitat Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD et al (2008) The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135(2):419–428PubMedCrossRef Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD et al (2008) The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135(2):419–428PubMedCrossRef
8.
Zurück zum Zitat Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P et al (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338(21):1481–1487PubMedCrossRef Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P et al (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338(21):1481–1487PubMedCrossRef
9.
Zurück zum Zitat Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R, Porteous ME et al (2006) Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354(26):2751–2763PubMedCrossRef Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R, Porteous ME et al (2006) Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354(26):2751–2763PubMedCrossRef
10.
Zurück zum Zitat Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ et al (1998) Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58(15):3455–3460PubMed Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ et al (1998) Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58(15):3455–3460PubMed
11.
Zurück zum Zitat Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P et al (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26(35):5783–5788PubMedCrossRef Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P et al (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26(35):5783–5788PubMedCrossRef
12.
Zurück zum Zitat Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P et al (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352(18):1851–1860PubMedCrossRef Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P et al (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352(18):1851–1860PubMedCrossRef
13.
Zurück zum Zitat Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X et al (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293(16):1986–1994PubMedCrossRef Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X et al (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293(16):1986–1994PubMedCrossRef
14.
Zurück zum Zitat Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M et al (2000) Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 18(11):2193–2200PubMed Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M et al (2000) Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 18(11):2193–2200PubMed
15.
Zurück zum Zitat Society AC (2012) Cancer treatment and survivorship facts & figures 2012–2013. Am Cancer Soc, Altanta Society AC (2012) Cancer treatment and survivorship facts & figures 2012–2013. Am Cancer Soc, Altanta
16.
Zurück zum Zitat Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN (2009) EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 11(1):42–65PubMedCrossRef Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN (2009) EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 11(1):42–65PubMedCrossRef
17.
Zurück zum Zitat Weissman SM, Burt R, Church J, Erdman S, Hampel H, Holter S et al (2012) Identification of individuals at risk for lynch syndrome using targeted evaluations and genetic testing: national Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. J Genet Couns 21(4):484–493PubMedCrossRef Weissman SM, Burt R, Church J, Erdman S, Hampel H, Holter S et al (2012) Identification of individuals at risk for lynch syndrome using targeted evaluations and genetic testing: national Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. J Genet Couns 21(4):484–493PubMedCrossRef
18.
Zurück zum Zitat Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH et al (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296(12):1507–1517PubMedCrossRef Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH et al (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296(12):1507–1517PubMedCrossRef
20.
Zurück zum Zitat Vasen HF, de Vos Tot Nederveen Cappel WH (2006) An evidence-based review on surveillance for Lynch syndrome. Dis Colon Rectum 49(11):1797–1798 (author reply 9) Vasen HF, de Vos Tot Nederveen Cappel WH (2006) An evidence-based review on surveillance for Lynch syndrome. Dis Colon Rectum 49(11):1797–1798 (author reply 9)
21.
Zurück zum Zitat Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, Peltomaki P, Aaltonen LA, Mecklin JP (2009) Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27(28):4793–4797PubMedCrossRef Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, Peltomaki P, Aaltonen LA, Mecklin JP (2009) Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27(28):4793–4797PubMedCrossRef
22.
Zurück zum Zitat Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5):829–834PubMedCrossRef Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5):829–834PubMedCrossRef
23.
Zurück zum Zitat Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354(3):261–269PubMedCrossRef Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354(3):261–269PubMedCrossRef
24.
Zurück zum Zitat Recommendations from the EGAPP Working Group (2009) genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11(1):35–41CrossRef Recommendations from the EGAPP Working Group (2009) genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11(1):35–41CrossRef
25.
Zurück zum Zitat Beamer LC, Grant ML, Espenschied CR, Blazer KR, Hampel HL, Weitzel JN et al (2012) Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol 30(10):1058–1063PubMedCrossRef Beamer LC, Grant ML, Espenschied CR, Blazer KR, Hampel HL, Weitzel JN et al (2012) Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol 30(10):1058–1063PubMedCrossRef
26.
Zurück zum Zitat Porteous M, Dunckley M, Appleton S, Catt S, Dunlop M, Campbell H et al (2003) Is it acceptable to approach colorectal cancer patients at diagnosis to discuss genetic testing? A pilot study. Br J Cancer 89(8):1400–1402PubMedCrossRef Porteous M, Dunckley M, Appleton S, Catt S, Dunlop M, Campbell H et al (2003) Is it acceptable to approach colorectal cancer patients at diagnosis to discuss genetic testing? A pilot study. Br J Cancer 89(8):1400–1402PubMedCrossRef
Metadaten
Titel
How do we approach the goal of identifying everybody with Lynch Syndrome?
verfasst von
Heather Hampel
Albert de la Chapelle
Publikationsdatum
01.06.2013
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 2/2013
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-013-9611-5

Weitere Artikel der Ausgabe 2/2013

Familial Cancer 2/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.